Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASH 2023

9 - 12 Dec 2023

San Diego, United States of America

ASH 2023: Study shows CAR-T cell therapy safe, effective even for high-risk patients

ASH 2023: Study shows CAR-T cell therapy safe, effective even for high-risk patients

ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia

ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia

ASH 2023: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax

ASH 2023: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax

ASH 2023: Combination immunotherapy produces high response rate in early results of trial targeting high-risk follicular lymphoma

ASH 2023: Combination immunotherapy produces high response rate in early results of trial targeting high-risk...

ASH 2023: Patients with a common form of acute myeloid leukemia report better quality of life when treatment includes new drug quizartinib

ASH 2023: Patients with a common form of acute myeloid leukemia report better quality of life when treatment...

ASH 2023: Landscape for AML patients evolving rapidly as research discoveries advance new treatments

ASH 2023: Landscape for AML patients evolving rapidly as research discoveries advance new treatments

ASH 2023: Collaborators leads to new treatment options for advanced myelofibrosis, other blood malignancies

ASH 2023: Collaborators leads to new treatment options for advanced myelofibrosis, other blood malignancies

ASH 2023: Cell therapy appears safe and effective for lymphoma in remission

ASH 2023: Cell therapy appears safe and effective for lymphoma in remission

ASH 2023: Hodgkin lymphoma prognosis, biology tracked with circulating tumour DNA

ASH 2023: Hodgkin lymphoma prognosis, biology tracked with circulating tumour DNA

ASH 2023: New personalised therapy improves survival for patients with CLL leukaemia

ASH 2023: New personalised therapy improves survival for patients with CLL leukaemia

ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia

ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia

ASH 2023: Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated

ASH 2023: Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for...

ASH 2023: Combination immunotherapy produces high response rate in early results of trial targeting high-risk follicular lymphoma

ASH 2023: Combination immunotherapy produces high response rate in early results of trial targeting high-risk...

ASH 2023: Third-generation anti-CD19 CAR T-cells demonstrate efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial

ASH 2023: Third-generation anti-CD19 CAR T-cells demonstrate efficacy without neurotoxicity in B-cell lymphoma...

ASH 2023: Patients with a common form of acute myeloid leukaemia report better quality of life when treatment includes new drug quizartinib

ASH 2023: Patients with a common form of acute myeloid leukaemia report better quality of life when treatment...

ASH 2023: Cell therapy appears safe and effective for lymphoma in remission

ASH 2023: Cell therapy appears safe and effective for lymphoma in remission

ASH 2023: Study provides insight into underlying gene mutations in myelodysplastic syndromes

ASH 2023: Study provides insight into underlying gene mutations in myelodysplastic syndromes

ASH 2023: Pilot study uses circulating tumour DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma

ASH 2023: Pilot study uses circulating tumour DNA to reliably predict relapse in patients with diffuse large B...

ASH 2023: Bispecific antibody drives myeloma precursor condition to undetectable levels in phase II trial

ASH 2023: Bispecific antibody drives myeloma precursor condition to undetectable levels in phase II trial

More from ecancer